国泰海通证券股份有限公司 关于上海奥浦迈生物科技股份有限公司 首次公开发行部分限售股上市流通的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）首次公开 发行股票并在科创板上市持续督导的保荐机构，根据《证券发行上市保荐业务管 理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作》等法律法规的相关规定，对奥浦迈首次 公开发行部分限售股上市流通事项进行了核查，核查情况及核查意见如下： 一、本次上市流通的限售股类型 经中国证券监督管理委员会（以下简称"中国证监会"）于 2022 年 6 月 13 日出具的《关于同意上海奥浦迈生物科技股份有限公司首次公开发行股票注册的 批复》（证监许可〔2022〕1232 号），同意上海奥浦迈生物科技股份有限公司 （以下简称"奥浦迈"或者"公司"）首次公开发行股票的注册申请，并经上海证券 交易所同意，公司首次向社会公众公开发行人民币普通股 2,049.5082 万股，并于 2022 年 9 月 2 日在上海证券交易所科创板上市。公司首次公 ...

Core Viewpoint - Shanghai OPM Biosciences Co., Ltd. reported significant growth in revenue and net profit for the first half of 2025, driven by strong market demand and effective cost management [1][6][7]. Financial Performance - The company achieved operating revenue of RMB 177.75 million, a year-on-year increase of 23.77% compared to RMB 143.61 million in the same period last year [6][7]. - Total profit reached RMB 48.85 million, marking a 62.55% increase from RMB 30.05 million in the previous year [6][7]. - Net profit attributable to shareholders was RMB 37.55 million, up 55.55% from RMB 24.14 million in the prior year [6][7]. - The net cash flow from operating activities surged to RMB 61.34 million, a remarkable increase of 271.78% compared to RMB 16.50 million in the same period last year [6][7]. Key Financial Indicators - Basic earnings per share rose to RMB 0.33, reflecting a 57.14% increase from RMB 0.21 in the previous year [7]. - The weighted average return on net assets increased to 1.78%, up from 1.13% [7]. - Research and development expenses accounted for 13.58% of operating revenue, compared to 10.71% in the previous year [7]. Business Development - The company has expanded its product offerings, with 282 confirmed drug development pipelines utilizing its cell culture products, an increase of 35 from the end of 2024 [6][7]. - Service business revenue also improved, showing a growth of 13.24% compared to the previous year [6][7]. Shareholder Returns - The company proposed a cash dividend of RMB 2.30 per 10 shares, contingent on meeting profit distribution conditions for the first half of 2025 [1].

上海奥浦迈生物科技股份有限公司2025 年半年度报告摘要 公司代码：688293 公司简称：奥浦迈 上海奥浦迈生物科技股份有限公司 二〇二五年八月 上海奥浦迈生物科技股份有限公司2025 年半年度报告摘要 其中，为进一步回报广大股东，若公司 2025 年上半年盈利且满足现金分红条件，拟于 2025 年半 年度报告披露时增加一次中期分红，预计 2025 年中期现金分红金额不低于 2,500 万元。同时股东 大会授权董事会在符合利润分配的条件下制定具体的 2025 年度中期利润分配方案。 结合 2025 年半年度公司实际经营情况及财务状况，公司拟以权益分派实施股权登记日的股份 总数为基数，向全体股东每 10 股派发现金红利人民币 2.30 元（含税）。截至 2025 年 6 月 30 日， 公司总股本为 113,548,754 股，预计合计分配现金红利 26,116,213.42 元（含税），占公司 2025 年 半年度合并报表归属于上市公司股东净利润的 69.56%，占公司累计未分配利润的 23.80%。 □适用 √不适用 上海奥浦迈生物科技股份有限公司2025 年半年度报告摘要 第一节 重要提示 规划，投资者 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-062 上海奥浦迈生物科技股份有限公司 关于公司 2025 年中期利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 司2025年中期利润分配预案的议案》，监事会认为，公司本次2025年度中期利润 分配预案，充分考虑了公司日常运营及长远发展，结合了公司盈利情况、现金流 状态和资金需求等综合因素，同时合理考虑了股东回报，不存在损害中小股东利 益的情形，符合公司目前的生产经营情况，有利于公司持续、健康、长远发展。 监事会同意公司2025年中期利润分配预案。 关于公司2025年中期利润分配预案具体内容如下： 现金红利26,116,213.42元（含税），占2025年半年度当期合并报表归属于上市公 司股东净利润的69.56%；占公司合并报表累计未分配利润的23.80%。 根据《上海奥浦迈生物科技股份有限公司2025年半年度报告》（未经审计）， 截至2025年6月30日，上海奥浦迈生物科技股份有限公司（以下简称"公司"或 "奥浦迈"）202 ...

Core Points - The company held the fourth meeting of the second board of independent directors on August 21, 2025, via online communication, with all three independent directors present [1] - The meeting approved the adjustment of the estimated amount for certain daily related transactions for 2025, increasing the expected sales amount to Suzhou Haixing Biotechnology Co., Ltd. from 50,000 yuan to 1,000,000 yuan, and the expected purchase amount from NAPU Analysis Technology (Suzhou) Co., Ltd. from 300,000 yuan to 400,000 yuan [1] - The total estimated amount for daily related transactions for 2025 was adjusted from 4,460,000 yuan to 5,510,000 yuan, while other previously estimated amounts remained unchanged [1] Summary of Related Sections - The independent directors concluded that the adjustments to the estimated amounts for daily related transactions were necessary for the company's normal production and operations, reflecting business development and market demand changes [2] - The pricing policy for daily related transactions adheres to principles of openness, fairness, and justice, with transaction prices settled at market rates, ensuring no adverse impact on the company's financial status or operational results [2] - The adjustments do not create dependency on related parties and do not affect the company's business independence, with the proposal requiring further review by the company's board of directors [2]

证券代码：688293 证券简称：奥浦迈 公告编号：2025-060 上海奥浦迈生物科技股份有限公司 第二届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）第二 届董事会第十一次会议于2025年8月21日通过现场表决与通讯相结合的方式召开。 本次会议通知及相关资料已于2025年8月11日送达全体董事。本次会议由董事长 肖志华先生召集并主持，会议应出席董事7名，实际出席董事7名，本次会议的召 集、召开方式符合相关法律、行政法规、部门规章、规范性文件和《公司章程》 的规定，会议决议合法有效。 二、董事会会议审议情况 表决结果：7票同意、0票反对、0票弃权；获全体董事一致通过。 具体内容详见公司于同日刊载于上海证券交易所网站（www.sse.com.cn）的 《上海奥浦迈生物科技股份有限公司2025年半年度报告》及《上海奥浦迈生物科 技股份有限公司2025年半年度报告摘要》。 上述议案在提交董事会审议前已经审计委员会 ...

上海奥浦迈生物科技股份有限公司 第二届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688293 证券简称：奥浦迈 公告编号：2025-061 一、监事会会议召开情况 上海奥浦迈生物科技股份有限公司（以下简称"奥浦迈"或"公司"）第二 届监事会第十次会议于2025年8月21日通过现场表决与通讯相结合的方式召开。 本次会议通知及相关资料已于2025年8月11日送达全体监事。本次会议由监事会 主席梁欠欠女士召集并主持，会议应出席监事3名，实际出席监事3名，本次会议 的召集、召开方式符合相关法律、行政法规、部门规章、规范性文件和《公司章 程》的规定，会议决议合法有效。 专项报告>的议案》 监事会认为：公司2025年半年度募集资金存放与实际使用情况符合《上海证 券交易所科创板股票上市规则》《上市公司募集资金监管规则》《上海奥浦迈生 物科技股份有限公司募集资金管理办法》等相关法律法规和公司制度的规定，公 司募集资金使用专户存储和专项使用，并及时履行了相关信息披露义务，募集资 金的使用审议程序合法 ...

品说明书（产品代码：NSH07654） 招商银行智汇系列看涨两层区间 7 天结构性存款产品 说明书（产品代码：FSH07881） 杭州银行"添利宝"结构性存款（挂钩汇率 B 款）协 议 杭州银行"添利宝"结构性存款（挂钩汇率 B 款）协 议 杭州银行大额存单 1,000.00 2025/3/24 2026/2/14 3.100 尚未到期 尚未到期 杭州银行"添利宝"结构性存款（挂钩汇率 B 款）协 1,600.00 2025/1/17 2025/7/27 2.300 尚未到期 尚未到期 议 招商银行定期存款 15,000.00 2025/1/24 2025/7/24 1.500 尚未到期 尚未到期 杭州银行"添利宝"结构性存款（挂钩汇率 B 款）协 议 招商银行点金系列看涨两层区间 91 天结构性存款产 品说明书（产品代码：NSH07999） 招商银行点金系列看涨两层区间 91 天结构性存款产 品说明书（产品代码：NSH08050） 杭州银行"添利宝"结构性存款（挂钩汇率 B 款）协 议（TLBB202509961） 杭州银行"添利宝"结构性存款（挂钩汇率 B 款）协 议（TLBB202509840） 杭州银 ...

Group 1 - The company will hold a half-year performance briefing on September 3, 2025, from 13:00 to 14:00 [1][2] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][3] - Key personnel attending the briefing include the Chairman, General Manager, CFO, independent directors, and the Secretary of the Board [2] Group 2 - Investors can submit questions for the briefing from August 27, 2025, to September 2, 2025, before 16:00 [3] - The company encourages participation through the Shanghai Stock Exchange Roadshow Center website [3] - After the briefing, investors can access the main content and details of the event on the same website [3]

Core Viewpoint - The company is committed to enhancing its core business and competitiveness through increased R&D investment and operational efficiency, while also focusing on investor returns and sustainable growth [1][5][6] Group 1: Business Focus and R&D Investment - The company specializes in cell culture products and services, aiming to provide comprehensive solutions for the biopharmaceutical industry [1] - R&D investment has consistently exceeded 10% of annual revenue, with a focus on developing proprietary technologies and expanding product lines [11][10] - The company has developed multiple new cell culture media products, enhancing its competitive edge in therapeutic protein production [12][13] Group 2: Financial Performance and Market Expansion - The sales revenue from cell culture products increased by 25.49% year-on-year, driven by the steady progress of client pipelines and rapid overseas expansion [2] - The company served over 700 domestic and international biopharmaceutical enterprises and research institutions, solidifying its market position [2][10] - The CDMO service business also showed positive growth, with a revenue increase of 13.24% compared to the previous year [2] Group 3: Investor Relations and Return Mechanisms - The company maintains a stable cash dividend policy, distributing a total of 22,709,750.80 yuan in cash dividends for the 2025 mid-year [5][6] - A share repurchase plan was completed, with a total transaction amount of 50,998,163.75 yuan, aimed at enhancing long-term investment value [7][8] - The company plans to implement a mid-year profit distribution of 2.30 yuan per share, amounting to 26,116,213.42 yuan, which represents 69.56% of the net profit for the first half of 2025 [6] Group 4: Internal Management and Quality Control - The company has successfully passed ISO9001:2015 quality management system audits, demonstrating its commitment to high-quality standards [16] - Continuous improvement in internal control systems and governance structures is prioritized to enhance operational efficiency and risk management [19][20] - The company emphasizes talent development, with over 70% of R&D personnel holding master's or doctoral degrees, fostering a strong innovation culture [17][18] Group 5: Future Outlook and Strategic Initiatives - The company is actively pursuing a major asset restructuring to enhance operational quality and risk resilience [17][18] - Plans to explore various share repurchase methods to strengthen capital structure and enhance investor value are in place [8] - The company aims to expand its international market presence while continuously optimizing product offerings and service quality [15][16]